Histaminergic gene polymorphisms associated with sedation in clozapine-treated patients

Eur Neuropsychopharmacol. 2017 May;27(5):442-449. doi: 10.1016/j.euroneuro.2017.03.009. Epub 2017 Apr 8.

Abstract

Sedation is a common adverse effect of clozapine treatment, which may be partly related to clozapine binding to histamine receptors in the central nervous system. The objective of this study was to investigate whether single nucleotide polymorphisms (SNPs) in the histaminergic system are associated with sedation in clozapine-treated patients. The study population comprised 237 clozapine-treated, Finnish, Caucasian patients that were diagnosed with schizophrenia and 176 were genotyped using Illumina HumanCoreExome-12 BeadChip. Sedation levels were assessed using self-rating questions from the Liverpool University Neuroleptic Side Effect Rating Scale (LUNSERS). The relationships between 55 different SNPs in the histaminergic system and adverse sedation effects were examined. SNPs were analyzed separately, and in groups, to formulate a genetic risk score (GRS). A permutation test was performed to avoid type I errors. Eight linked SNPs (r2 = 1) in the HNMT gene were also associated with sedation according to the GLM, adjusted for age, gender and BMI (false-discovery-rate-adjusted p = 0.013). An association on a trend level between a GRS of four different SNPs (recessive histamine N-methyltransferase HNMT rs2737385, additive histamine receptor H1 rs1552498, dominant HRH1 rs17034063 and recessive amine oxidase, copper containing 1 AOC1 rs6977381) and sedation was found (permuted p-value = 0.066) in a generalized linear model (GLM) incorporating age, gender and body mass index (BMI; adjusted R2 = 0.22). Polymorphisms in genes encoding histamine receptors or enzymes related to histamine metabolism may explain individual variation in sedative effects experienced during clozapine treatment.

Keywords: Adverse events; Antipsychotic agents; Clozapine; Histamine; Sedation; Single nucleotide polymorphism.

MeSH terms

  • Adult
  • Amine Oxidase (Copper-Containing) / genetics
  • Antipsychotic Agents / adverse effects*
  • Chi-Square Distribution
  • Clozapine / adverse effects*
  • Conscious Sedation
  • Female
  • Finland
  • Genotype
  • Histamine N-Methyltransferase / genetics*
  • Humans
  • Male
  • Middle Aged
  • Neuroleptic Malignant Syndrome / etiology
  • Neuroleptic Malignant Syndrome / genetics
  • Polymorphism, Single Nucleotide / genetics*
  • Receptors, Histamine / genetics*
  • Regression Analysis
  • Schizophrenia / drug therapy*
  • Schizophrenia / genetics
  • Severity of Illness Index

Substances

  • Antipsychotic Agents
  • Receptors, Histamine
  • Amine Oxidase (Copper-Containing)
  • Histamine N-Methyltransferase
  • Clozapine